Immuneering/$IMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Ticker
$IMRX
Sector
Primary listing
Employees
55
Headquarters
Website
Immuneering Metrics
BasicAdvanced
$285m
-
-$1.06
0.36
-
Price and volume
Market cap
$285m
Beta
0.36
52-week high
$10.08
52-week low
$2.29
Average daily volume
1.9m
Financial strength
Current ratio
32.449
Quick ratio
31.501
Long term debt to equity
1.606
Total debt to equity
1.806
Profitability
EBITDA (TTM)
-58.876
Management effectiveness
Return on assets (TTM)
-27.89%
Return on equity (TTM)
-43.84%
Valuation
Price to book
1.38
Price to tangible book (TTM)
1.43
Price to free cash flow (TTM)
-4.532
Free cash flow yield (TTM)
-22.06%
Free cash flow per share (TTM)
-0.973
Growth
Earnings per share change (TTM)
-45.84%
3-year earnings per share growth (CAGR)
-18.21%
What the Analysts think about Immuneering
Analyst ratings (Buy, Hold, Sell) for Immuneering stock.
Immuneering Financial Performance
Revenues and expenses
Immuneering Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs